News
-

Semaglutide and Aging: The New Study Is in Mice
A new Nature study found longer life and better physical function in old female mice given semaglutide. It did not test people, so it cannot tell us that semaglutide slows human aging or adds years to human life.
-

Semaglutide L-Carnitine: What the Additive Means
Some compounders add L-carnitine for its role in fat metabolism. The rationale is real biology, but no human trial shows that mixing it with semaglutide improves weight-loss outcomes.
-

Semax for ADHD: What the Evidence Actually Shows
Semax has not been tested in a human ADHD trial. The attention claims come from a small study in healthy volunteers, neurological research, and a biological hypothesis—not evidence that it treats ADHD.
-

Tesamorelin for Women: Evidence and Menopause
Tesamorelin for women has limited female-specific evidence: pivotal trials enrolled 84%–86% men, and no trial was designed for menopause-related abdominal change. Hormone therapy, pregnancy, glucose and IGF-1 all change the prescribing conversation.
-

Tesamorelin Injections: Sites, Timing, and Storage
Tesamorelin is injected under the skin once daily. The abdomen, site rotation, timing, device format, and storage instructions all matter—and they are not identical across branded and compounded formulations.
-

What Is Semax Used For? Evidence and Status
Semax is used in Russia for defined neurological and optic-nerve indications. In the United States, interest centers on focus and memory, but the human evidence for those nootropic uses is small and indirect.
-

BPC-157 Arginate vs Acetate: What Changes?
Arginate and acetate name salt forms of the same 15-amino-acid peptide. The counter-ion may change formulation properties, but no published in-vivo comparison shows that one produces better clinical outcomes.
-

Does Tesamorelin Work? What the Trials Show
Tesamorelin reduced visceral abdominal fat in two large phase 3 trials, but those studies involved adults with HIV-associated lipodystrophy. The evidence does not establish it as a general weight-loss medication or promise the same result for every patient.
-

DSIP Benefits: What the Human Evidence Shows
DSIP has been studied most directly for sleep, but the human findings are small, old and mixed. Signals involving ACTH, chronic pain and withdrawal are preliminary rather than established benefits.
-

Is Semaglutide a GLP-1? What the Class Means
Yes. Semaglutide is a GLP-1 receptor agonist and an engineered peptide. Those labels describe two different things: the receptor it activates and the structure of the medication.
-

KLOW Peptide Side Effects: What the Evidence Shows
KLOW peptide side effects do not yet have reliable rates or a complete clinical list. The blend combines four peptides, so its clearest known risks are injection-site reactions, immune reactions, compounding-related problems, and effects that human studies have not measured.
-

N-Acetyl Semax Amidate: Claims vs Evidence
N-acetyl Semax amidate caps both ends of Semax, but the stability and potency claims run ahead of the evidence: no published human trial has tested this variant.
-

Semaglutide Pyridoxine: What Vitamin B6 Adds
Semaglutide/pyridoxine is a compounded combination of semaglutide and vitamin B6. Some compounders add B6 with nausea in mind, but no clinical trial has shown that the combination reduces GLP-1 nausea.
-

Sermorelin for Men: Testosterone, Muscle & Sleep
Sermorelin can stimulate growth-hormone release when the pituitary responds, but it is not testosterone therapy. Small studies in older men found biochemical changes and mixed body-composition or strength results, with no reliable sleep or recovery benefit established.
-

Sermorelin Tablets: Do Oral Forms Work?
Tablets, troches and rapid-dissolve forms sound simpler than an injection. The unresolved question is whether they deliver intact sermorelin into the bloodstream in a reliable amount.
-

Tirzepatide vs Semaglutide Side Effects
Neither medication has fewer side effects in every setting: dose, treatment population and the individual matter more than a simple ranking.
-

BPC-157 Half-Life: What the Evidence Shows
The human half-life of BPC-157 has not been established. Animal studies measured the intact peptide in minutes, not hours, while detection tests and biological effects answer different questions.
-

KPV Peptide Benefits: What the Evidence Shows
KPV's strongest benefit signals are lower inflammatory activity in cultured cells and mouse colitis models. No human trial has established a KPV benefit, dose, or safety profile.
-

LillyDirect Tirzepatide vs Compounded Tirzepatide
LillyDirect supplies branded Zepbound in fixed-strength single-dose vials. Compounded tirzepatide is prepared by a licensed pharmacy for an individual prescription, so it is a different finished product and a different fulfillment route.
-

PT-141 Benefits: What the Human Trials Show
The strongest evidence is specific: studies found higher desire scores and less distress about low desire in premenopausal women with HSDD. Earlier, smaller trials in men measured erectile response, not broad sexual performance.
Page 18 of 27 · 528 articles